COVID-19 vaccine immunogenicity in people with HIV
COVID-19 vaccine immunogenicity in people with HIV
Simple item page
Full item details
- creativework.keywords - en
- AIDS Vaccines*
- Antibodies
- COVID-19 Vaccines
- COVID-19* / prevention & control
- Canada
- HIV Infections*
- Humans
- Immunogenicity, Vaccine
- Prospective Studies
- RNA, Viral
- SARS-CoV-2
- dc.contributor.author
- Costiniuk, Cecilia T.
- Galipeau, Yannick
- Harris, Marianne
- Hull, Mark
- Brumme, Zabrina L.
- Lapointe, Hope R.
- Brockman, Mark A.
- Margolese, Shari
- Mandarino, Enrico
- Samarani, Suzanne
- Vulesevic, Branka
- Lebouché, Bertrand
- Angel, Jonathan B.
- Routy, Jean-Pierre
- Cooper, Curtis L.
- Anis, Aslam H.
- Lee, Terry
- Kovacs, Colin
- Jenabian, Mohammad-Ali
- Chambers, Catharine
- Brockman, Mark A.
- Samji, Hasina
- Burchell, Ann N.
- Ostrowski, Mario
- Tan, Darrell H. S.
- Walmsley, Sharon
- Singer, Joel
- Hull, Mark
- Brumme, Zabrina L.
- Lapointe, Hope R.
- dc.date.accessioned
- 2024-07-15T20:18:31Z
- dc.date.available
- 2024-07-15T20:18:31Z
- dc.date.issued
- 2023-01-01
- dc.description.abstract - en
- OBJECTIVES: Many vaccines require higher/additional doses or adjuvants to provide adequate protection for people with HIV (PWH). Our objective was to compare COVID-19 vaccine immunogenicity in PWH to HIV-negative individuals. DESIGN: In a Canadian multi-center prospective, observational cohort of PWH receiving at least two COVID-19 vaccinations, we measured vaccine-induced immunity at 3 and 6 months post 2nd and 1-month post 3rd doses. METHODS: The primary outcome was the percentage of PWH mounting vaccine-induced immunity [co-positivity for anti-IgG against SARS-CoV2 Spike(S) and receptor-binding domain proteins] 6 months post 2nd dose. Univariable and multivariable logistic regressions were used to compare COVID-19-specific immune responses between groups and within subgroups. RESULTS: Data from 294 PWH and 267 controls were analyzed. Immunogenicity was achieved in over 90% at each time point in both groups. The proportions of participants achieving comparable anti-receptor-binding domain levels were similar between the group at each time point. Anti-S IgG levels were similar by group at month 3 post 2nd dose and 1-month post 3rd dose. A lower proportion of PWH vs. controls maintained vaccine-induced anti-S IgG immunity 6 months post 2nd dose [92% vs. 99%; odds ratio: 0.14 (95% confidence interval: 0.03, 0.80; P = 0.027)]. In multivariable analyses, neither age, immune non-response, multimorbidity, sex, vaccine type, or timing between doses were associated with reduced IgG response. CONCLUSION: Vaccine-induced IgG was elicited in the vast majority of PWH and was overall similar between groups. A slightly lower proportion of PWH vs. controls maintained vaccine-induced anti-S IgG immunity 6 months post 2nd dose demonstrating the importance of timely boosting in this population.
- dc.description.sponsorship
- Supported by funding from the Public Health Agency of Canada, through the Vaccine Surveillance Reference group and the COVID-19 Immunity Task Force (grant number: 2122-HQ-000075), and the CTN (grant number: N/A). Production of COVID-19 reagents was financially supported by the National Research Council of Canada (NRC)'s Pandemic Response Challenge Program.
- dc.identifier.doi
- https://doi.org/10.1097/QAD.0000000000003429
- dc.identifier.issn
- 1473-5571
- dc.identifier.pubmedID
- 36476452
- dc.identifier.uri
- https://open-science.canada.ca/handle/123456789/2692
- dc.language.iso
- en
- dc.publisher - en
- Wolters Kluwer Health, Inc.
- dc.publisher - fr
- Wolters Kluwer Health, Inc.
- dc.rights - en
- Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
- dc.rights - fr
- Creative Commons Attribution - Pas d'utilisation commerciale - Pas de modification 4.0 International (CC BY-NC-ND 4.0)
- dc.rights.openaccesslevel - en
- Gold
- dc.rights.openaccesslevel - fr
- Or
- dc.rights.uri - en
- https://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.rights.uri - fr
- https://creativecommons.org/licenses/by-nc-nd/4.0/deed.fr
- dc.subject - en
- Health
- dc.subject - fr
- Santé
- dc.subject.en - en
- Health
- dc.subject.fr - fr
- Santé
- dc.title - en
- COVID-19 vaccine immunogenicity in people with HIV
- dc.type - en
- Article
- dc.type - fr
- Article
- local.article.journalissue
- 1
- local.article.journaltitle
- AIDS
- local.article.journalvolume
- 37
- local.pagination
- F1-F10
- local.peerreview - en
- Yes
- local.peerreview - fr
- Oui
- local.requestdoi - en
- No
- local.requestdoi - fr
- No
Download(s)
Original bundle
1 - 1 of 1
Name: costiniuk-covid-19-vaccine-immunogenicity-in-people-with-hiv.pdf
Size: 704.5 KB
Format: PDF
Collection(s)